Table 2.
Spirometry measurements at 40 days post-COVID-19.
| Variables (Mean ± SD) | Mild (n = 22) | Moderate (n = 22) | Severe (n = 22) | p-Value |
|---|---|---|---|---|
| FVC | 106.0 ± 18.9 | 93.8 ± 21.2 | 86.8 ± 25.5 | 0.018 * |
| FEV1 | 98.7 ± 22.0 | 92.6 ± 20.3 | 87.4 ± 24.2 | 0.248 |
| FEV1/FVC | 80.6 ± 7.3 | 82.5 ± 5.0 | 84.0 ± 9.3 | 0.319 |
| FEF25–75 | 82.9 ± 5.6 | 79.2 ± 6.4 | 77.7 ± 6.0 | 0.017 * |
| AMPI | 85.9 ± 14.3 | 90.6 ± 11.9 | 92.4 ± 13.3 | 0.249 |
| Result (n, %) | ||||
| Ventilatory dysfunction | 5 (22.7%) | 9 (40.9%) | 13 (59.1%) | 0.049 |
| Post-COVID-19 fibrosis | 3 (13.6%) | 5 (22.7%) | 11 (50.0%) | 0.021 |
| Normal | 14 (63.6%) | 9 (40.9%) | 6 (27.3%) | 0.049 |
*—Significant on post hoc analysis; SD—Standard Deviation; FVC (Forced Vital Capacity); FEV1 (Forced Expiratory Volume in 1 s); FEF25–75 (Forced Expiratory Flow 25–75%); AMPI—Airway Microvascular Permeability.